COVID-19 Related Lung Ventilation and Perfusion Injury

August 11, 2025 updated by: McMaster University

Prospective Longitudinal Study to Characterize and Understand the Clinical Relevance of SARS-CoV2 Related Ventilation and Perfusion Injury Evaluated by V/Q SPECT-CT in an Asthmatic and Healthy Population

Little is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. This lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life. Therefore, towards the goal of understanding the effects of COVID-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of COVID-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmatic and healthy population. To do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with COVID-19 will be studied.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
42

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • St. Joseph's Healthcare Hamilton

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

community sample

Description

Inclusion Criteria:

For all participants:

  • Males and females ≥ 18 years of age
  • Individuals able and willing to provide written informed consent
  • Individuals able and willing to comply with the study protocol

For participants with asthma:

  • Individuals with physician confirmed asthma (12% bronchodilator reversibility or PC20 methacholine less than 8mg/ml)
  • Individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-T2 biologics

For participants who recently recovered from covid-19:

  • Individuals previously diagnosed with covid-19 confirmed by FLOQswab test
  • Individuals who recently (≤4-weeks) recovered from covid-19

Exclusion Criteria:

For all participants:

  • Males and females < 18 years of age
  • Individuals who are unable to read and/or understand English
  • Individuals who are pregnant or breastfeeding
  • Individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history
  • Individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained
  • Individuals who are unable to complete one or more study manoeuvres

For participants with no history of lung disease:

  • Individuals with a history of respiratory infection or disease

For participants who have not been diagnosed with covid-19:

  • Individuals who have previously had covid-19 confirmed by FLOQswab test

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
healthy COVID-19+
Individuals who recently recovered from COVID-19 and who have no history of lung disease
Other: V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
Other: St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
Other: mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Other: Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Other: Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Other: Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Other: Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
asthmatic COVID-19+
Individuals who recently recovered from COVID-19 and who have asthma
Other: V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
Other: St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
Other: mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Other: Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Other: Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Other: Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Other: Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
healthy COVID-19-
Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
Other: V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
Other: St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
Other: mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Other: Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Other: Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Other: Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Other: Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
asthmatic COVID-19-
Individuals who have not been diagnosed with COVID-19 and who have asthma
Other: V/Q SPECT-CT
At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
Other: St. George's Respiratory Questionnaire (SGRQ)
At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
Other: mMRC (Modified Medical Research Council) Dyspnea Scale
At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Other: Six-minute walk test (6MWT)
At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Other: Spirometry
At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Other: Plethysmography & DLCO
At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Other: Airwave Oscillometry
At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in lung ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Short-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
The short-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
≤4-weeks post COVID-19 recovery (Visit 1)
Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
The long-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
6-months post COVID-19 recovery (Visit 2)
Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic
Time Frame: 6-months post COVID-19 recovery (Visit 2)
Difference in the 6-month change in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
6-months post COVID-19 recovery (Visit 2)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery (Visit 1).
≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery (Visit 1).
≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery (Visit 1).
≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery
Time Frame: ≤4-weeks post COVID-19 recovery (Visit 1)
In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery (Visit 1).
≤4-weeks post COVID-19 recovery (Visit 1)
Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery
Time Frame: 6-months post COVID-19 recovery (Visit 2)
In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery (Visit 2).
6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery
Time Frame: 6-months post COVID-19 recovery (Visit 2)
In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery (Visit 2).
6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery
Time Frame: 6-months post COVID-19 recovery (Visit 2)
In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery (Visit 2).
6-months post COVID-19 recovery (Visit 2)
Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery
Time Frame: 6-months post COVID-19 recovery (Visit 2)
In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery (Visit 2).
6-months post COVID-19 recovery (Visit 2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
McMaster University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Research St. Joseph's - Hamilton
Cyclomedica Australia Pty Ltd

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Sarah Svenningsen, PhD, McMaster University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 18, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 26, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 26, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 28, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 14, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 16, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 14, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FIRH002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will not be shared with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings